ImmunityBio, Inc. (IBRX) Revenue by Segment
ImmunityBio revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), ImmunityBio's largest product or service was Product, with $50.67 million or 99% of revenue, up 91.8% from a year earlier. Next: Other (1%).
By region, United States brought in 99% and Europe brought in 1% of revenue in Q2 fiscal 2026.
By country, UNITED STATES brought in 99% and Europe brought in 1% of revenue in Q2 fiscal 2026.
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q2 fiscal 2023.
ImmunityBio, Inc.
Revenue breakdown
Fiscal quarters, from company filings
ImmunityBio revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Product | $50.7M | $44.2M | $31.8M | $26.4M | 99% |
| Other | $568,000 | $39,000 | $281,000 | $4,000 | 1% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
ImmunityBio revenue by region, last 4 quarters
| Region | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q3 FY24 | Share |
|---|---|---|---|---|---|
| United States | $50.7M | $44.2M | $31.8M | $6.0M | 99% |
| Europe | $518,000 | $24,000 | $262,000 | $120,000 | 1% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
ImmunityBio revenue by country, last 4 quarters
| Country | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| UNITED STATES | $50.7M | $44.2M | $31.8M | $26.4M | 99% |
| Europe | $518,000 | $24,000 | $262,000 | – | 1% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
Which product or service makes the most money for ImmunityBio?
Product: $50.67 million, or 99% of revenue, in Q2 fiscal 2026.
What are ImmunityBio's main products and services?
By revenue in Q2 fiscal 2026: Product (99%) and Other (1%).
Where does ImmunityBio make its money?
By region in Q2 fiscal 2026: United States (99%) and Europe (1%).
